SEI Investments’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.52M | Sell |
48,452
-15,119
| -24% | -$446K | ﹤0.01% | 2094 |
|
|
2026
Q1 | $1.57M | Sell |
63,571
-13,501
| -18% | -$322K | ﹤0.01% | 2126 |
|
|
2025
Q4 | $1.8M | Buy |
77,072
+430
| +0.6% | +$9.58K | ﹤0.01% | 1909 |
|
|
2025
Q3 | $1.51M | Buy |
76,642
+9,344
| +14% | +$192K | ﹤0.01% | 1800 |
|
|
2025
Q2 | $1.46M | Sell |
67,298
-34,975
| -34% | -$826K | ﹤0.01% | 1768 |
|
|
2025
Q1 | $2.48M | Sell |
102,273
-14,045
| -12% | -$316K | ﹤0.01% | 1554 |
|
|
2024
Q4 | $2.43M | Buy |
116,318
+14,849
| +15% | +$319K | ﹤0.01% | 1614 |
|
|
2024
Q3 | $2.02M | Buy |
101,469
+17,011
| +20% | +$315K | ﹤0.01% | 1674 |
|
|
2024
Q2 | $1.31M | Buy |
84,458
+1,098
| +1% | +$17.1K | ﹤0.01% | 1815 |
|
|
2024
Q1 | $1.33M | Buy |
83,360
+32,621
| +64% | +$492K | ﹤0.01% | 1779 |
|
|
2023
Q4 | $853K | Buy |
50,739
+8,483
| +20% | +$116K | ﹤0.01% | 1928 |
|
|
2023
Q3 | $494K | Sell |
42,256
-3,241
| -7% | -$43.4K | ﹤0.01% | 2111 |
|
|
2023
Q2 | $611K | Sell |
45,497
-29,640
| -39% | -$427K | ﹤0.01% | 2059 |
|
|
2023
Q1 | $1.25M | Buy |
75,137
+29,150
| +63% | +$481K | ﹤0.01% | 1802 |
|
|
2022
Q4 | $855K | Sell |
45,987
-173,465
| -79% | -$2.67M | ﹤0.01% | 1819 |
|
|
2022
Q3 | $2.82M | Sell |
219,452
-129,714
| -37% | -$1.54M | 0.01% | 1377 |
|
|
2022
Q2 | $2.44M | Buy |
349,166
+53,452
| +18% | +$392K | 0.01% | 1456 |
|
|
2022
Q1 | $2.44M | Buy |
295,714
+121,870
| +70% | +$862K | ﹤0.01% | 1467 |
|
|
2021
Q4 | $1.18M | Hold |
173,844
| – | – | ﹤0.01% | 1782 |
|
|
2021
Q3 | $921K | Buy |
+173,844
| New | +$951K | ﹤0.01% | 1808 |
|
|
2021
Q2 | – | Sell |
-18,905
| Closed | -$63K | – | 2557 |
|
|
2021
Q1 | $63K | Hold |
18,905
| – | – | ﹤0.01% | 2455 |
|
|
2020
Q4 | $63K | Hold |
18,905
| – | – | ﹤0.01% | 2431 |
|
|
2020
Q3 | $56K | Sell |
18,905
-58,179
| -75% | -$228K | ﹤0.01% | 2369 |
|
|
2020
Q2 | $356K | Hold |
77,084
| – | – | ﹤0.01% | 2006 |
|
|
2020
Q1 | $297K | Buy |
77,084
+64,316
| +504% | +$264K | ﹤0.01% | 1942 |
|
|
2019
Q4 | $48K | Buy |
+12,768
| New | +$59.7K | ﹤0.01% | 2363 |
|
|
2019
Q2 | – | Sell |
-112,169
| Closed | -$572K | – | 2460 |
|
|
2019
Q1 | $572K | Buy |
+112,169
| New | +$330K | ﹤0.01% | 1822 |
|
|
2018
Q2 | – | Sell |
-1,250
| Closed | -$3K | – | 3635 |
|
|
2018
Q1 | $3K | Hold |
1,250
| – | – | ﹤0.01% | 3152 |
|
|
2017
Q4 | $5K | Buy |
+1,250
| New | +$4.13K | ﹤0.01% | 2940 |
|
Other funds holding CPRX
GCL
HI
SEI Investments's CPRX Position: Q2 2026 in Review
SEI Investments reduced its Catalyst Pharmaceutical (CPRX) stake by 24% in Q2 2026, selling an estimated $446K and leaving 48,452 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2094.
SEI Investments first reported a position in CPRX in Q4 2017 and has held it in 29 quarters since. The position peaked at $2.82M in Q3 2022. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.
- SEI Investments held 48,452 shares of Catalyst Pharmaceutical worth $1.52M as of Q2 2026.
- SEI Investments sold 15,119 Catalyst Pharmaceutical shares in Q2 2026, an estimated $446K.
- Catalyst Pharmaceutical made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #2094 holding.
- SEI Investments first reported a position in Catalyst Pharmaceutical in Q4 2017 and has held it in 29 quarters since.
- SEI Investments's Catalyst Pharmaceutical position peaked at $2.82M in Q3 2022.
- 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.
Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.